Evaluation of the Pharmacokinetics of IPX237 Formulations in Healthy Volunteers

Trial Profile

Evaluation of the Pharmacokinetics of IPX237 Formulations in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Esketamine (Primary) ; Esketamine (Primary) ; Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors IMPAX Laboratories; Impax Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2014 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 28 Nov 2013 Planned initiation date changed from 25 Nov 2013 to 9 Dec 2013 as reported by Australian New Zealand Clinical Trials Registry.
    • 12 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top